Hypersensitivity pneumonitis associated with the use of trofosfamide

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 603-604

  Kopp, H G ^a   Kanz, L ^a   Hartmann, J T ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hypersensitivity pneumonitis; Pulmonary toxicity; Trofosfamide

Indexed keywords

PREDNISOLONE; TROFOSFAMIDE;

AGED; ALLERGIC PNEUMONITIS; ARTICLE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; METASTASIS; NERVE SHEATH TUMOR; PRIORITY JOURNAL; SIDE EFFECT;

EID: 3142776162     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131682.21637.69     Document Type: Article

References (5)

1. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res. 2003; 23(2C):1899-1901.
2. Hempel G, Krumpelmann S, May-Manke A, Hohenlochter B, Blaschke G, Jurgens H, et al. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. Cancer Chemother Pharmacol 1997; 40:45-50.
3. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997; 17:146S-154S.
4. Baker WJ, Fistel SJ, Jones RV, Weiss RB. Interstitial pneumonitis associated with ifosfamide therapy. Cancer 1990; 65:2217-2221.
5. Marshkin L, Prince HM, Rischin D, Zimet A. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant 2001; 27:559-563.